Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03645824

Collaborator

Dutch Cancer Society (Other), CTI BioPharma (Industry)

Enrollment

Locations

Arm

104

Anticipated Duration (Months)

5.1

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.

Condition or Disease	Intervention/Treatment	Phase
Myelofibrosis	Drug: Pacritinib	Phase 2

Detailed Description

Despite recent new therapeutic options, allogeneic Stem Cell Transplantation remains the only curative option in patients with Myelofibrosis. Therefore, optimalization of this therapy remains a major challenge. Improvement of the clinical condition of these patients, decreasing spleen size can be accomplished by JAK2 inhibitor treatment and might improve SCT outcome. In addition, selective JAK2 inhibitors might modulate GvHD which can also add to improved SCT outcome. Also, decreasing the burden/activity of the disease before allo-SCT might also improve final disease response. The first, limited, clinical data of ruxolitinib treatment before allo-SCT show controversial effects on the outcome of SCT. Therefore, additional prospective clinical trials have to be done to establish the role of JAK2 inhibition before allogeneic SCT. Since ruxolitinib has considerable myelosuppressive effects which might limit the clinical use in some MF patients, other selective JAK2 inhibitors might be useful in this setting. Pacritinib, as a JAK2/FLT3 inhibitor, has a very potent JAK2 inhibitory activity without myelosuppressive effects and might therefore be more suitable than ruxolitinib. The major possible side effects are gastro-intestinal and can be managed with medication. In several studies, pacritinib has shown to be effective in decreasing spleen size and has shown to improve clinical condition of patients. Therefore, this compound seems promising in improving the outcome of allo-SCT. Although pacritinib causes no inhibition of JAK1 activity and therefore might have limited effects in decreasing inflammatory response, this might also be of benefit since a "withdrawal syndrome" as has been described after cessation of ruxolitinib is not to be expected.

With this trial, using pacritinib treatment before allo-SCT, the issue of improvement of SCT outcome will be investigated.

Study Design

Study Type:

Interventional

Actual Enrollment :

61 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Trial in Patients With Myelofibrosis (Primary, Post-ET or Post PV-MF) Treated With the Selective JAK2 Inhibitor Pacritinib Before Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation

Actual Study Start Date :

Jun 4, 2018

Anticipated Primary Completion Date :

Jul 1, 2023

Anticipated Study Completion Date :

Feb 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pacritinib treatment befor allo-SCT The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.	Drug: Pacritinib Patients receive up to 4 cycles of pacritinib before allo-SCT

Arm

Intervention/Treatment

Experimental: Pacritinib treatment befor allo-SCT

The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.

Drug: Pacritinib

Patients receive up to 4 cycles of pacritinib before allo-SCT

Outcome Measures

Primary Outcome Measures

Proportion of patients receiving allo-SCT, with failure within or at day 180 post-transplant. [2 years]
Failure can be defined by one of the following parameters: Primary graft failure Acute graft versus host disease grade 3-4 Secondary graft failure Death, from any cause

Secondary Outcome Measures

Adverse events [5 years]
Adverse events will be monitored.
Progression free survival [5 years]
Progression free survival as time between registration or SCT until progression/relapse or death from any cause
Overall survival [5 years]
Over all survival, calculated from either registration or SCT.
Relapse mortality [5 years]
Death due to the disease or after progression
Non-relapse mortality [5 years]
Death not due to disease or relapse
Quality of life during and after treatment [5 years]
Quality of life during and after treatment will be recorded by use of the MPN-SAF questionnaire. From a total of 27 questions, the scores (from 0 to 10) from the following 10 questions are added and subsequently averaged to come to a total quality of life score. fatigue satisfction after a meal stomach complaints not able to perform activities concentration problems night sweat itch bone pain fever sudden weight loss

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with a confirmed diagnosis of post-ET, post-PV or primary myelofibrosis
Intermediate-2 or high-risk according to DIPSS plus (Appendix E)
Age 18-70 years inclusive
WHO performance status 0-2 (Appendix C)
All men and women of childbearing potential must agree to use adequate contraception during the study
Written informed consent
Patient is capable of giving informed consent

Exclusion Criteria:

Previous treatment with JAK2 inhibitors within 2 weeks of study inclusion. Patients who have been treated with pacritinib as their previous JAK2 inhibitor treatment cannot participate in this study
Any GI or metabolic condition (e.g. inflammatory or chronic functional bowel disorder such as Crohn's Disease, Inflammatory Bowel Disease, chronic diarrhea or constipation) that could interfere with absorption of oral medication
Left ventricular cardiac ejection fraction of ≤ 45% by echocardiogram or multigated acquisition (MUGA) scan
Impaired liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), >3 × the upper limit of normal (ULN) (AST/ALT >5 × ULN if transaminase elevation is related to MF), direct bilirubin >4× ULN, and creatinine clearance ˂ 40 ml/min.
Impaired coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (APTT)>1.5 x ULN.
Experimental treatment within four weeks before inclusion for PMF, Post-PV, or Post-ET MF
Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D)
Treatment with a potent strong CYP3A4 inhibitor or a strong cytochrome P450 (CYP450) inducer within the last 2 weeks
Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ≤100 mg per day, within the last 2 weeks
New York Heart Association Class II, III, or IV congestive heart failure
QTc prolongation >450 ms as assessed by ECG and corrected by Federicia method or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)
Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the principal investigator, if stable and unlikely to affect patient safety.
Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the principal investigator, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
Patients with active, uncontrolled infections
Patients known to be HIV (human immunodeficiency virus)-positive
Active hepatitis A, B or C
History of active malignancy during the past 3 years, except basal carcinoma of the skin or stage 0 cervical carcinoma
Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.)
Pregnant or breastfeeding women
Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Contacts and Locations

Locations

	Site	City	Country
1	BE-Antwerpen-ZNASTUIVENBERG	Antwerpen	Belgium
2	BE-Gent-UZGENT	Gent	Belgium
3	BE-Leuven-UZLEUVEN	Leuven	Belgium
4	BE-Roeselare-AZDELTA	Roeselare	Belgium
5	NL-Amsterdam-AMC	Amsterdam	Netherlands
6	NL-Amsterdam-VUMC	Amsterdam	Netherlands
7	NL-Groningen-UMCG	Groningen	Netherlands
8	NL-Maastricht-MUMC	Maastricht	Netherlands
9	NL-Nijmegen-RADBOUDUMC	Nijmegen	Netherlands
10	NL-Rotterdam-EMCDANIEL	Rotterdam	Netherlands
11	NL-Rotterdam-ERASMUSMC	Rotterdam	Netherlands
12	NL-Utrecht-UMCUTRECHT	Utrecht	Netherlands